ClinicalTrials.gg
RecruitingNCT07266116Updated May 8, 2026

Assessment of the Efficacy and Safety of Injectable TQB2934 (Subcutaneous Injection) in Systemic Light Chain Amyloidosis Patients

A Phase 1/2 interventional study of TQB2934 injection in Systemic Light Chain Amyloidosis, sponsored by Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.. Recruiting at 27 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-05-08.

Sponsored by Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2025; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
70
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 32 studies in Amyloidosis with a site in China — 21 open to participants now, 25 under way, 3 of them phase 3. Amyloidosis · China.

Planned enrollment
10th of 24
70 · median 53
Started
2025
with 7 others
Phase 1/2
4 of 32
4 open now
Primary completion
2029-02
later than 18 of 24 live
Registered
28th of 32
by date

Among the 32 studies in Amyloidosis with a site in China, this one is the 10th largest by planned enrollment of the 24 interventional ones that give a count, is one of 8 that started in 2025, is one of 4 in phase 1/2, reaches primary completion later than 18 of the 24 other live ones, and was the 28th registered.

Amyloidosis

290 studies on the registry are indexed under Amyloidosis; 92 are open to participants now.

Browse Amyloidosis studies →

Open to participants now

21 of the 32 studies in Amyloidosis with a site in China are open now. Recruiting first, the newest first:

15 more — sign in →

All 21 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 70 Amyloidosis studies recruiting now, 43 (61%) set no upper age limit and 3 (4%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Amyloidosis with a site in China, or all of them as a file.
02

Study summary

This study is a clinical trial aimed at the marketing of TQB2934 for injection. The project plans to enroll 70 subjects, including 13-21 subjects in Phase Ib, to evaluate the safety and preliminary efficacy, pharmacokinetic (PK) characteristics, immunogenicity, and pharmacodynamic (PD) of TQB2934 for injection in subjects with systemic light chain amyloidosis, and to determine the recommended Phase II dose (RP2D). The Phase II plan involves enrolling 49 subjects, aiming to demonstrate that in adult subjects with relapsed/refractory systemic light chain amyloidosis who have previously received treatment with daratumumab and bortezomib, TQB2934 for injection significantly improves the hematological complete response (CR) rate compared to historical controls. The primary endpoint is the optimal hematological CR rate.

03

Conditions studied

  • Systemic Light Chain Amyloidosis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The subjects voluntarily joined this study, signed the form, and exhibited good compliance;
  • Aged 18 to 80 years old, with an (ECOG) score of 0 to 2, and an expected survival of more than 12 weeks;
  • Systemic light chain amyloidosis with diagnostic records (i.e., primary light chain amyloidosis);
  • Presence of ;
  • At least one organ involved;
  • Have previously received at least one , and recurred and progressed after the remission of the last line treatment;
  • N-terminal pro-B-type natriuretic peptide (NT-proBNP) ≤ 8500 ng/L;
  • The corresponding organ function conforms to the protocol requirements;
  • Women of childbearing age should agree to use during the study period and for 6 months after its completion; they must have a negative serum pregnancy test within 7 days before enrollment in the study and must be non-lactating subjects; men should agree to use contraception during the study period and for 6 months after its completion.

Exclusion criteria

Exclusion Criteria:

  • Diagnosed with other types of amyloidosis, active plasma cell leukemia, active multiple myeloma, etc.
  • Have received hematopoietic stem cell transplantation within 1 year prior to the first dose, or have received autologous hematopoietic stem cell transplantation within 12 weeks prior to the first dose;
  • Previously received treatment with drugs targeting the same target;
  • Within 4 weeks prior to the first dose, the patient has received a cumulative dose of dexamethasone >160 mg or an equivalent dose of other , or within 3 weeks prior to the first dose, the patient has received targeted therapy, cytotoxic drugs, or any antibody therapy, or within 2 weeks prior to the first dose, the patient has received proteasome inhibitor therapy or radiotherapy, or within 1 week prior to the first dose, the patient has received immunomodulator therapy;
  • Those who have received treatment with traditional Chinese patent medicines and simple preparations with clear anti-tumor indications specified in the National Medical Products Administration (NMPA) approved drug instructions within 2 weeks before the first administration;
  • Those who have received attenuated within 4 weeks before the first dose or plan to receive attenuated live vaccine during the study period;
  • Individuals with a history of severe allergies of unknown cause, or known allergies to monoclonal antibody drugs or exogenous human immunoglobulins, or known allergies to the in injectable TQB2934 or pharmaceutical preparations;
  • Having had or currently suffering from other malignant tumors within 3 years before the first medication;
  • Unresolved toxic reactions above Common Terminology Criteria (CTC) AE Grade 1 caused by any previous treatment;
  • Those who have undergone major surgical treatment, significant traumatic injury, or are expected to undergo major surgery during the study treatment period within 4 weeks before the first dose of medication;
  • Arterial/venous thromboembolic events occurred within 6 months before the first dose;
  • Individuals with a history of abuse of psychotropic drugs who are unable to quit or who have mental disorders; or intractable seizures that require treatment;
  • Those with unsatisfactory blood pressure control;
  • Patients with poorly controlled diabetes;
  • Patients who have active or uncontrolled severe bacterial, viral, or systemic fungal infections (≥CTC AE Grade 2 infections) within 4 weeks before the first dose of medication;
  • Patients with hepatitis or decompensated liver cirrhosis ( Class B or C);
  • Individuals with active tuberculosis, history of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonia, radiation pneumonia requiring treatment, or clinically symptomatic active pneumonia;
  • Those who have experienced asthma within 2 years before the first medication or currently suffer from asthma or ;
  • Individuals with significant cardiovascular diseases;
  • Individuals with a history of immune deficiency, or active diseases requiring systemic therapy, etc.
  • Exclude subjects with organ failure unrelated to systemic light-chain (AL) amyloidosis;
  • Subjects deemed unsuitable for enrollment by the researchers.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    TQB2934 injection

    TQB2934 injection 40 mg and 60 mg During cycles 1-3, medication is administered once a week. From the end of cycles 4-6, medication is administered once every two weeks. For patients who have not achieved complete remission (CR) or have MRD positivity after six cycles of medication, medication is administered once every eight weeks, with a maximum treatment duration of no more than two years

    Drug: TQB2934 injection

Interventions

  • TQB2934 for injection is a bispecific antibody targeting B-cell maturation antigen (BCMA) and Cluster of Differentiation 3 (CD3). One end binds to the CD3 receptor on the surface of T cells, while the other end binds to BCMA, recruiting T cells to BCMA-positive cells. This can activate T cells, which then release granzyme, perforin, and other enzymes to kill BCMA-positive malignant plasma cells, thereby reducing the level of monoclonal immunoglobulin light chains in the body and delaying further organ damage.

06

What researchers measure

Primary outcomes

  1. Numbers of subjects with adverse events (AEs), abnormal laboratory test values, and serious adverse events (SAEs)

    The occurrence of all adverse events (AEs), serious adverse events (SAEs), incidence and severity of adverse events (AEs), abnormal laboratory test values, and serious adverse events (SAEs).

    Time frame: Baseline to the end of the study, about 4 years

  2. The best hematological response evaluated by the Independent Review Committee (IRC) is complete remission (CR)

    Percentage of subjects who achieved complete hematological remission (CR) after receiving TQB2934 for injection among adult subjects with relapsed/refractory systemic light chain amyloidosis who had previously received treatment with duramycin and bortezomib.

    Time frame: Baseline to CR,about 1.5 years

Secondary outcomes

  1. Peak concentration (Cmax)

    Maximum plasma drug concentration.

    Time frame: Pre-dose Cycle 1 day 1/day 8, post dose Cycle 1 day 8/Cycle 3 day 1 2, 6, 24, 48, 72, 120 hours; pre-dose cycle 1 day 15, 22,cycle 2 day 1, cycle 4 day 1, cycle 6 day 1, cycle 12 day 1 and EOT

  2. Immunogenicity incidence rate and its changes over time

    Immunogenicity incidence rate and its changes over time

    Time frame: pre-dose day 8, cycle 2 day 1, cycle 6 day 1, cycle 12 day 1 and End of Treatment (EOT)

  3. Exploring the correlation between soluble BCMA in peripheral blood and the efficacy of TQB2934

    Exploring the correlation between soluble BCMA in peripheral blood and the efficacy of TQB2934

    Time frame: pre-dose cycle 1 day 1, day 8, cycle 2 day 1, cycle 3 day 1, cycle 6 day 1, cycle 12 day 1; post dose cycle 1 day 1/day 8/cycle 3 day 1 6 hours; 56 days after the last administration

  4. The best hematologic complete remission rate evaluated by researchers

    The percentage of subjects with complete remission, which is the best hematological response evaluated by researchers.

    Time frame: Baseline to CR, about 1.5 years

  5. Best overall hematologic response rate

    Percentage of subjects with best hematologic response of complete remission (CR), very good partial remission (VGPR), and partial remission (PR)

    Time frame: Baseline to CR/VGPR/PR, about 1.5 years

  6. Minimal residual disease (MRD) negative rate

    Percentage of subjects achieving MRD negativity.

    Time frame: Baseline to MRD negativity, about 1.5 years

  7. Duration of hematologic response (DOR)

    Among subjects with the best hematological response of CR, VGPR, or PR, the time from the date of first achieving PR or higher response to the date of hematological progression, major organ (heart or kidney) failure, or death (from any cause).

    Time frame: The first date of PR/ VGPR/ CR to PD/ major organ failure /die, about 1.5 years

  8. Duration of complete hematological remission (DOCR)

    Among subjects with the best hematological response of CR, the time from the date of first achieving CR to the date of hematological progression, major organ (heart or kidney) failure, or death (from any cause).

    Time frame: The first date of CR to PD/ major organ failure /die, about 1.5 years

  9. Cardiac relief rate

    Percentage of subjects who achieve cardiac remission according to the International Society for Transfusion Medicine (ISA) criteria.

    Time frame: Baseline to Cardiac relief, about 1.5 years

  10. Renal remission rate

    Percentage of subjects achieving renal remission according to International Society of Amyloidosis (ISA) criteria.

    Time frame: Baseline to Renal remission, about 1.5 years

  11. Liver response rate

    Percentage of subjects achieving liver remission according to the International Society of Transfusion Medicine (ISA) criteria.

    Time frame: Baseline to liver remission, about 1.5 years

  12. Main organ dysfunction progression-free survival (MOD-PFS)

    The time from the date of initial medication to the date of hematological progression, major organ (heart or kidney) failure, or death (from any cause).

    Time frame: The first date of initial medication to PD/ major organ failure /die, about 2 years

  13. Major Organ Dysfunction-Event-Free Survival (MOD-EFS)

    The time period from the date of initial medication to the date of hematological progression, major organ (heart or kidney) failure, change of treatment regimen due to poor efficacy or intolerance to toxicity, or death (from any cause).

    Time frame: The first date of initial medication to PD/ major organ failure /die, about 2 years

  14. Overall survival (OS)

    The time from the date of initial medication to the date of death from any cause

    Time frame: The first date of initial medication to die, about 2 years

07

Study locations

1 of 27 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2025 (actual). Primary completion is estimated for Feb 2029, 38 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 25, 2025
First posted
Dec 5, 2025
StartActual
Dec 26, 2025
Primary completionEst.
Feb 2029
CompletionEst.
Nov 2029
Last update
May 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07266116
Responsible party
Sponsor
First posted
Dec 5, 2025
Start date
Dec 26, 2025
Primary completion
Feb 2029 (estimated)
Completion
Nov 2029 (estimated)
Last update
May 8, 2026

Study contacts

Jin Lu, Doctor
Contact
jinllu@sina.com
13311491805

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-CD3/Anti-BCMA Bispecific Antibody TQB2934

Start the discussion